ProCE Banner Activity

VESPER: Phase III Trial of Perioperative Chemotherapy With Dose-Dense MVAC vs Gemcitabine + Cisplatin in Patients With Muscle-Invasive Bladder Cancer

Slideset Download
Conference Coverage
Among patients with muscle-invasive bladder cancer, dose-dense MVAC significantly improved the 3-year rate of PFS and time to progression vs gemcitabine plus cisplatin in the neoadjuvant setting.

Released: September 27, 2021

Expiration: September 26, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc